LEXINGTON, Mass., July 1, 2021 /PRNewswire/ -- iSpecimen Inc.
(Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online
marketplace for human biospecimens, today announced the closing of
the issuance of an additional 337,500 shares of its common stock
pursuant to the full exercise of the underwriters' over-allotment
option in connection with the Company's initial public offering
(the "IPO"). The additional shares were sold at the initial
offering price of $8.00 per share,
resulting in additional gross proceeds of $2,700,000 and bringing the total gross proceeds
of the IPO to $20,700,000.
The shares of common stock began trading on the Nasdaq Capital
Market under the ticker symbol "ISPC" on June 17, 2021.
ThinkEquity, a division of Fordham Financial Management, Inc.,
acted as the sole book-running manager for the IPO of the
A registration statement relating to the IPO was declared
effective by the Securities and Exchange Commission ("SEC") on
June 16, 2021. A final prospectus
related to the IPO was filed and is available on the SEC's website
at www.sec.gov. The IPO was made only by means of a
prospectus. Electronic copies of the final prospectus may be
obtained from ThinkEquity, a division of Fordham Financial
Management, Inc., 17 State Street, 22nd Floor,
New York, New York 10004, by
telephone at (877) 436-3673 and by email
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
iSpecimen offers an online marketplace for human biospecimens,
connecting life scientists in commercial and non-profit
organizations with healthcare providers that have access to
patients and specimens needed for medical discovery. Proprietary,
cloud-based technology enables scientists to intuitively search for
specimens and patients across a federated partner network of
hospitals, labs, biobanks, blood centers, and other healthcare
organizations. For more information about iSpecimen, please
Forward Looking Statements
This press release contains statements that constitute
"forward-looking statements," including with respect to the IPO and
the anticipated use of the net proceeds. No assurance can be given
that the net proceeds of the IPO will be used as indicated.
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of the Company, including those set
forth in the Risk Factors section of the Company's registration
statement and final prospectus for the Company's offering filed
with the SEC. Copies of these documents are available on the SEC's
website at www.sec.gov. The Company undertakes no obligation
to update these statements for revisions or changes after the date
of this release, except as required by law.
View original content to download
SOURCE iSpecimen Inc.